Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ECOR NASDAQ:IRIX NASDAQ:NDRA NASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECORelectroCore$4.85+0.3%$6.01$4.16▼$19.49$36.74M0.36124,998 shs2,386 shsIRIXIRIDEX$1.29+0.8%$1.26$0.78▼$1.99$21.92M0.6389,582 shs5,591 shsNDRAENDRA Life Sciences$4.99+2.4%$5.40$2.90▼$22.68$3.74M-0.14643,709 shs1,579 shsSLNOSoleno Therapeutics$49.86-2.6%$76.37$41.50▼$90.32$2.66B-2.711.19 million shs47,765 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECORelectroCore+1.90%-1.83%-7.82%-4.92%-20.82%IRIXIRIDEX-3.03%-7.25%+13.27%+31.46%-36.32%NDRAENDRA Life Sciences+2.74%+16.79%+0.21%+46.69%-39.50%SLNOSoleno Therapeutics-4.57%-29.23%-28.56%-34.06%-3.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECORelectroCore$4.85+0.3%$6.01$4.16▼$19.49$36.74M0.36124,998 shs2,386 shsIRIXIRIDEX$1.29+0.8%$1.26$0.78▼$1.99$21.92M0.6389,582 shs5,591 shsNDRAENDRA Life Sciences$4.99+2.4%$5.40$2.90▼$22.68$3.74M-0.14643,709 shs1,579 shsSLNOSoleno Therapeutics$49.86-2.6%$76.37$41.50▼$90.32$2.66B-2.711.19 million shs47,765 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECORelectroCore+1.90%-1.83%-7.82%-4.92%-20.82%IRIXIRIDEX-3.03%-7.25%+13.27%+31.46%-36.32%NDRAENDRA Life Sciences+2.74%+16.79%+0.21%+46.69%-39.50%SLNOSoleno Therapeutics-4.57%-29.23%-28.56%-34.06%-3.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceECORelectroCore 3.00Buy$25.50427.95% UpsideIRIXIRIDEX 0.00N/AN/AN/ANDRAENDRA Life Sciences 3.00Buy$50.00926.69% UpsideSLNOSoleno Therapeutics 3.08Buy$115.09124.92% UpsideCurrent Analyst Ratings BreakdownLatest NDRA, SLNO, ECOR, and IRIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025SLNOSoleno TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/27/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$106.008/20/2025SLNOSoleno TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$123.008/18/2025SLNOSoleno TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.00 ➝ $110.008/7/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/7/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$97.00 ➝ $106.008/7/2025SLNOSoleno TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$105.00 ➝ $110.007/11/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$105.00 ➝ $121.006/23/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/23/2025SLNOSoleno TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$110.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookECORelectroCore$27.70M1.32N/AN/A$1.13 per share4.27IRIXIRIDEX$48.67M0.45N/AN/A$0.13 per share9.85NDRAENDRA Life SciencesN/AN/AN/AN/A$4.77 per shareN/ASLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateECORelectroCore-$11.89M-$1.62N/AN/AN/A-47.84%-221.93%-69.17%11/12/2025 (Estimated)IRIXIRIDEX-$8.91M-$0.33N/A∞N/A-10.95%-386.93%-17.42%11/11/2025 (Estimated)NDRAENDRA Life Sciences-$11.51M-$33.89N/AN/AN/AN/A-194.14%-127.89%11/21/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/5/2025 (Estimated)Latest NDRA, SLNO, ECOR, and IRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025NDRAENDRA Life Sciences-$2.27-$1.71+$0.56-$1.71N/AN/A8/12/2025Q2 2025IRIXIRIDEX-$0.09-$0.06+$0.03-$0.06$13.10 million$13.57 million8/6/2025Q2 2025ECORelectroCore-$0.32-$0.35-$0.03-$0.44$7.24 million$7.38 million8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthECORelectroCoreN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioECORelectroCoreN/A1.100.95IRIXIRIDEX62.291.961.34NDRAENDRA Life SciencesN/A3.213.21SLNOSoleno Therapeutics0.2115.1315.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipECORelectroCore26.74%IRIXIRIDEX20.10%NDRAENDRA Life Sciences1.19%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipECORelectroCore13.80%IRIXIRIDEX7.40%NDRAENDRA Life Sciences0.04%SLNOSoleno Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableECORelectroCore507.58 million6.54 millionNot OptionableIRIXIRIDEX12016.99 million15.74 millionOptionableNDRAENDRA Life Sciences20750,000753,000Not OptionableSLNOSoleno Therapeutics3053.15 million49.74 millionOptionableNDRA, SLNO, ECOR, and IRIX HeadlinesRecent News About These CompaniesWhat is Lifesci Capital's Estimate for SLNO Q3 Earnings?September 14 at 6:34 AM | marketbeat.comSLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 13 at 3:15 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.- SLNOSeptember 13 at 2:45 PM | prnewswire.comSoleno Therapeutics (NASDAQ:SLNO) Upgraded to Strong-Buy at Lifesci CapitalSeptember 13 at 7:21 AM | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Trading Down 8.9% - What's Next?September 12, 2025 | marketbeat.comRosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNOSeptember 12, 2025 | prnewswire.comOptimize Financial Inc Makes New Investment in Soleno Therapeutics, Inc. $SLNOSeptember 12, 2025 | marketbeat.comWoodline Partners LP Grows Stock Position in Soleno Therapeutics, Inc. $SLNOSeptember 12, 2025 | marketbeat.comFred Alger Management LLC Has $2.89 Million Holdings in Soleno Therapeutics, Inc. $SLNOSeptember 12, 2025 | marketbeat.comSOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the FirmSeptember 11, 2025 | globenewswire.comSoleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens BermanSeptember 11, 2025 | globenewswire.comAre Legal Probes Shaping Trust in Soleno Therapeutics’ (SLNO) Drug Pipeline and Investor Relations?September 11, 2025 | finance.yahoo.comSoleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerSeptember 11, 2025 | zacks.comSoleno Therapeutics (SLNO) Falls Hard on Patient DeathSeptember 11, 2025 | msn.comSoleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs MuraSeptember 10, 2025 | businesswire.comSLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law FirmSeptember 10, 2025 | businesswire.comSoleno Therapeutics stock falls after patient death reportSeptember 10, 2025 | in.investing.comUnpacking the Latest Options Trading Trends in Soleno TherapeuticsSeptember 10, 2025 | benzinga.comSoleno drops on death of patient treated with Vykat XRSeptember 10, 2025 | msn.comSoleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details InsideSeptember 10, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNOSeptember 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesFree Cash Flow Boom Keeps Microsoft Ahead of the PackBy Chris Markoch | August 29, 2025Semtech: Bullish Market Forces Come Into Alignment for This StockBy Thomas Hughes | August 27, 2025Zscaler Shares Can Hit a Fresh High Before Year-EndBy Thomas Hughes | September 3, 2025Royal Caribbean Earnings Beat Fuels Strong 2025 OutlookBy Jeffrey Neal Johnson | August 22, 2025Improving Fundamentals Drive New Buybacks for 3 Strong PerformersBy Leo Miller | August 29, 2025NDRA, SLNO, ECOR, and IRIX Company DescriptionselectroCore NASDAQ:ECOR$4.84 +0.02 (+0.31%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.IRIDEX NASDAQ:IRIX$1.29 +0.01 (+0.78%) As of 09:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.ENDRA Life Sciences NASDAQ:NDRA$4.99 +0.12 (+2.36%) As of 09:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Soleno Therapeutics NASDAQ:SLNO$49.86 -1.31 (-2.56%) As of 10:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
